Archived explainer. For the current picture see today's HCM page.
Why Is HUTCHMED CHINA LTD ADR (HCM) Stock Up Today?
By the Top Tier Newswire AI Desk · September 4, 2026 at 12:05 AM ET · reviewed against 12 wire stories
HUTCHMED CHINA LTD ADR (HCM) is up +17.19% in the latest session. Our newswire has captured 12 stories on HCM across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
HCM stock is up 17.19% as of 9:30 AM EDT, trading at $14.11. The sharp rise follows the announcement of a licensing and co-development agreement with GlaxoSmithKline for HMPL-A830, a preclinical oncology asset. The deal has triggered a broad market response and reinforced investor confidence in the company’s strategic positioning in the cancer therapy space.
What Happened
HUTCHMED China Ltd ADR (NASDAQ:HCM) announced a commercialization agreement with GSK for ex-China rights to HMPL-A830, a KRAS-EGFR antibody-targeted therapy conjugate. The terms of the deal were not fully disclosed but are reported to be worth up to $1.3 billion. The partnership represents a significant milestone for HCM, expanding the potential reach of its oncology pipeline. The news was followed by a rating upgrade from Daiwa, which raised its stance on HCM to Buy from Hold. This upgrade added momentum to the stock’s move, which had already risen 13.7% earlier in the session.
What The Data Shows
The stock has moved up 15.9% over the past eight sessions, rising from $12.18 to $14.12. On September 3, 2026, it printed 12 fresh 52-week highs and three 52-week lows, reflecting mixed retail activity. HCM is currently trading within its 52-week range of $9.77 to $18.30. The stock’s beta of 0.44 indicates it is less volatile than the broader market. Despite a high P/E ratio of 596.3 and a year-to-date revenue decline of 8.8%, the recent partnership and analyst upgrade have driven a sharp reversal in sentiment.
What To Watch
The stock’s next key catalyst will be the release of its next earnings report, though no specific date is provided. Investors should also monitor the breadth of coverage and whether additional analysts follow Daiwa’s lead with upgrades.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
HCM · Sep 4 session (5-min) · -0.78% vs prior close · updated 8:56 PM ETAI sentiment, last 36h · averaged over 12 stories · 64/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
9d agoYahoo TopBULLISH 73M&A
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfr
9d agoThe FlyBULLISH 68Analyst
Hutchmed extends rally to 17% after Daiwa upgrades to Buy
9d agoThe FlyBULLISH 61Analyst
Hutchmed upgraded to Buy from Hold at Daiwa
9d agoSeeking AlphaBULLISH 63Product/PR
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 September 3, 2026 7:30 AM EDTCompany...
9d agoInvesting.com MarketsNEUTRAL 50General
Why is HUTCHMED stock surging today?
Why is HUTCHMED stock surging today?
9d agoThe FlyBULLISH 63General
Hutchmed rises 13.7%
9d agoTipRanksBULLISH 73M&A
HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal
HUTCHMED stock soared on Thursday after the company announced a new licensing deal with GlaxoSmithKline.
10d agoThe FlyBULLISH 56General
Hutchmed, GSK enter HMPL-A830 commercialization agreement
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →